YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics compa...
Offering Hope for Enhanced Early Detection and Patient Care in the Battle Against Cancer YONGIN, S...
* Recent updates on its development of LSD treatments were presented YONGIN, South Korea, Feb. 14...
YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that th...
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces th...
* To commence operation by 2027…with max. 400K liters of plasma production capacity per annum *...
* Completed the construction of a GMP pilot plant in its Hwasun production plant in Jeollanam-do,...
Recognized for its global-quality sample analysis services based on various analytical platforms Y...
- Collaboration includes the transfer of GC Genome's essential wet lab know-how for SNP genotyping ...
YONGIN, South Korea, Nov. 5, 2023 /PRNewswire/ -- GC Biopharma announced 1 Nov. 2023 that it has ap...
Brining Expertise in NK Cell Therapy to Advance Efforts in Cancer Prevention, early detection, and ...
- An innovative study of methylation markers and deep learning model enables precise lung cancer di...
YONGIN, South Korea, Oct. 10, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that it has p...
YONGIN, South Korea, Oct. 10, 2023 /PRNewswire/ -- GC Biopharma Corp. announced on today that it ha...
YONGIN, South Korea, Oct. 5, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that GC1126A, ...
* The first clinical trial sample analysis provider to adopt LIMS * To provide enhanced quality ...
With the participation of all affiliated group entities YONGIN, South Korea, Aug. 30, 2023 /PRNewsw...
YONGIN, South Korea, Aug. 25, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biophar...
* Analyzed the FDA FAERS data…to compare the thrombotic AEs of Hemlibra vs. FVIII replacements. Y...
YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceut...